Name | Number of supported studies | Average coverage | |
---|---|---|---|
placental villous trophoblast | 3 studies | 60% ± 6% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
placenta | 3 studies | 27% ± 10% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
ureter | 0% | 0 | 0 / 0 | 100% | 3.79 | 1 / 1 |
muscle | 98% | 40.73 | 789 / 803 | 0% | 0 | 0 / 0 |
uterus | 93% | 29.88 | 158 / 170 | 1% | 0.04 | 5 / 459 |
breast | 92% | 35.91 | 423 / 459 | 1% | 0.08 | 16 / 1118 |
thymus | 93% | 35.42 | 608 / 653 | 0% | 0 | 0 / 605 |
skin | 93% | 44.09 | 1682 / 1809 | 0% | 0 | 0 / 472 |
ovary | 90% | 32.03 | 162 / 180 | 1% | 0.01 | 4 / 430 |
intestine | 88% | 25.33 | 846 / 966 | 2% | 0.14 | 13 / 527 |
lung | 85% | 24.40 | 489 / 578 | 2% | 0.10 | 26 / 1155 |
brain | 85% | 23.90 | 2248 / 2642 | 2% | 0.04 | 11 / 705 |
blood vessel | 87% | 23.35 | 1155 / 1335 | 0% | 0 | 0 / 0 |
stomach | 84% | 19.63 | 300 / 359 | 3% | 0.46 | 8 / 286 |
adipose | 86% | 26.95 | 1031 / 1204 | 0% | 0 | 0 / 0 |
pancreas | 83% | 18.88 | 273 / 328 | 2% | 0.08 | 3 / 178 |
esophagus | 82% | 23.33 | 1183 / 1445 | 2% | 0.10 | 4 / 183 |
bladder | 81% | 25.71 | 17 / 21 | 3% | 0.32 | 15 / 504 |
prostate | 80% | 17.74 | 195 / 245 | 1% | 0.04 | 4 / 502 |
heart | 80% | 20.06 | 691 / 861 | 0% | 0 | 0 / 0 |
adrenal gland | 71% | 13.29 | 182 / 258 | 0% | 0 | 0 / 230 |
kidney | 58% | 9.24 | 52 / 89 | 1% | 0.06 | 7 / 901 |
spleen | 53% | 9.62 | 128 / 241 | 0% | 0 | 0 / 0 |
liver | 36% | 4.41 | 82 / 226 | 1% | 0.05 | 3 / 406 |
peripheral blood | 25% | 8.76 | 228 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
GO_0007520 | Biological process | myoblast fusion |
GO_0006949 | Biological process | syncytium formation |
GO_0009653 | Biological process | anatomical structure morphogenesis |
GO_0000768 | Biological process | syncytium formation by plasma membrane fusion |
GO_0005886 | Cellular component | plasma membrane |
Gene name | ERVW-1 |
Protein name | Syncytin-1 (Endogenous retrovirus group W member 1) (Env-W) (Envelope polyprotein gPr73) (Enverin) (HERV-7q Envelope protein) (HERV-W envelope protein) (HERV-W_7q21.2 provirus ancestral Env polyprotein) (Syncytin) [Cleaved into: Surface protein (SU) (gp50); Transmembrane protein (TM) (gp24)] |
Synonyms | ERVWE1 |
Description | FUNCTION: This endogenous retroviral envelope protein has retained its original fusogenic properties and participates in trophoblast fusion and the formation of a syncytium during placenta morphogenesis. May induce fusion through binding of SLC1A4 and SLC1A5 . .; FUNCTION: Endogenous envelope proteins may have kept, lost or modified their original function during evolution. Retroviral envelope proteins mediate receptor recognition and membrane fusion during early infection. The surface protein (SU) mediates receptor recognition, while the transmembrane protein (TM) acts as a class I viral fusion protein. The protein may have at least 3 conformational states: pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During viral and target cell membrane fusion, the coiled coil regions (heptad repeats) assume a trimer-of-hairpins structure, positioning the fusion peptide in close proximity to the C-terminal region of the ectodomain. The formation of this structure appears to drive apposition and subsequent fusion of membranes. |
Accessions | Q9UQF0 ENST00000603053.2 ENST00000493463.2 |